Evolving Landscape of Respiratory Viral Infections in Hematopoietic Cellular and CAR T-cell Therapy Recipients Post-COVID-19 Pandemic
Posted inHematology-Oncology Infectious Diseases news

Evolving Landscape of Respiratory Viral Infections in Hematopoietic Cellular and CAR T-cell Therapy Recipients Post-COVID-19 Pandemic

This study elucidates the incidence and characteristics of respiratory viral infections (RVIs) within 100 days following hematopoietic cell transplant and CAR T-cell therapy, highlighting SARS-CoV-2 as the predominant pathogen and identifying risk factors for severe infection in the post-pandemic era.
Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Posted inHematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.
Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma
Posted inHematology-Oncology news Oncology

Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma

This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating alloSCT for high-risk cases.
TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL
Posted inHematology-Oncology news Pediatrics

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Patients harboring TP53 mutations or deletions demonstrated markedly lower remission rates and substantially worse event-free and overall survival compared to TP53 wild-type counterparts.